THIS WARRANT
AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR
THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE
PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL
REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAW OR
SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT
FROM REGISTRATION.
WARRANT TO PURCHASE
STOCK
|
Company:
|
PEREGRINE
PHARMACEUTICALS, INC., a Delaware corporation
|
|
|
|
|
Number of
Shares:
|
507,614, plus
all Additional Shares which Holder is entitled to purchase pursuant
to Section 1.7
|
|
|
|
|
Class of
Stock:
|
Common
|
|
|
|
|
Warrant
Price:
|
$0.2955
|
|
|
|
|
Issue
Date:
|
December 19,
2008
|
|
|
|
|
Expiration
Date:
|
The 5
th anniversary after the Issue Date or the earlier
expiration of this Warrant pursuant to Section
1.6.2(A)(ii)
|
|
|
|
|
Credit
Facility:
|
This Warrant is
issued in connection with the Credit Extensions referenced in the
Loan and Security Agreement among Company, Avid BioServices, Inc.,
BlueCrest Capital Finance, L.P., as Administrative Agent and as a
lender, and the other lenders named therein, dated of even date
herewith (the “ Loan Agreement ”)
|
THIS WARRANT
CERTIFIES THAT, for good and valuable consideration, BlueCrest
Capital Finance, L.P. (“ BlueCrest ”, together
with any registered holder from time to time of this Warrant or any
holder of the shares issuable or issued upon exercise of this
Warrant, “ Holder ”) is entitled to purchase the
number of fully paid and nonassessable shares of the class of
securities (the “ Shares ”) of the Company at
the Warrant Price, all as set forth above and as adjusted pursuant
to Article 2 of this Warrant, subject to the provisions and upon
the terms and conditions set forth in this Warrant.
1.1
Method of Exercise . Holder may exercise this
Warrant by delivering a duly executed Notice of Exercise in
substantially the form attached as Appendix 1 to the principal
office of the Company. Unless Holder is exercising the
conversion right set forth in Article 1.2, Holder shall also
deliver to the Company a check, wire transfer (to an account
designated by the Company), or other form of payment acceptable to
the Company for the aggregate Warrant Price for the Shares being
purchased.
1.2
Conversion Right . In lieu of exercising this
Warrant as specified in Article 1.1, Holder may from time to time
convert this Warrant, in whole or in part, into a number of Shares
determined by dividing (a) the aggregate fair market value of the
Shares or other securities otherwise issuable upon exercise of this
Warrant being exercised minus the aggregate Warrant Price of such
Shares by (b) the fair market value of one Share. The
fair market value of the Shares shall be determined pursuant to
Article 1.3.
1.3.1 If
the Company’s common stock is traded in a public market, the
fair market value of each Share shall be the closing price of a
Share reported for the business day immediately before Holder
delivers its Notice of Exercise to the Company (or in the instance
where the Warrant is exercised immediately prior to the
effectiveness of the Company’s initial public offering, the
“price to public” per share price specified in the
final prospectus relating to such offering). If the
Company’s common stock is not traded in a public market, the
Board of Directors of the Company shall determine fair market value
in its reasonable good faith judgment (the “ Company
Determination ”).
1.3.2 If
the Holder disagrees with the Company Determination and by notice
to the Company given within twenty (20) days after receipt of
notice of the Company Determination (an " Appraisal Notice
") elects to dispute the Company Determination, such dispute shall
be resolved as set forth in Section 1.3.3 below.
1.3.3 For
a period of ten (10) days after the Appraisal Notice, the Company
and the Holder shall negotiate in good faith to resolve their
differences as to the determination of fair market
value. In the absence of a mutually satisfactory
resolution within such ten (10)-day period, the Company shall
within ten (10) days after the last day of such ten (10)-day period
engage an investment bank or other qualified appraisal firm
reasonably acceptable to the Holder (the " Appraiser ") to
make an independent determination of fair market value (the "
Appraiser Determination "). The Appraiser
Determination shall be made within sixty (60) days of the
engagement of such Appraiser, shall be evidenced in a written
report addressed to the Company and the Holder, and shall be final
and binding on the Company and the Holder. The costs of
the Appraiser Determination shall be borne (i) solely by the
Company if the difference between the Appraiser Determination and
the Company Determination is greater than ten percent (10%), (ii)
solely by the Holder if the difference between the Appraiser
Determination and the Company Determination is less than ten
percent (10%) and (iii) equally by the Company and the Holder if
the difference between the Appraiser Determination and the Company
Determination is equal to ten percent (10%).
1.4
Delivery of Certificate and New Warrant
. Promptly after Holder exercises or converts this
Warrant and, if applicable, the Company receives payment of the
aggregate Warrant Price, the Company shall deliver to Holder
certificates for the Shares acquired and, if this Warrant has not
been fully exercised or converted and has not expired, a new
Warrant representing the Shares not so acquired.
1.5
Replacement of Warrants . On receipt of evidence
reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, on delivery of an indemnity agreement
reasonably satisfactory in form and amount to the Company or, in
the case of mutilation on surrender and cancellation of this
Warrant, the Company shall execute and deliver, in lieu of this
Warrant, a new warrant of like tenor.
1.6
Treatment of Warrant Upon Acquisition of Company
.
1.6.1 "
Acquisition ". For the purpose of this Warrant,
"Acquisition" means any sale, license, or other disposition of all
or substantially all of the assets of the Company, or any
reorganization, consolidation, or merger of the Company where the
holders of the Company's securities before the transaction
beneficially own less than fifty percent (50%) of the outstanding
voting securities of the surviving entity after the
transaction.
1.6.2
Treatment of Warrant at Acquisition .
(A) Upon
the written request of the Company, Holder agrees that, in the
event of an Acquisition that is not an asset sale and in which the
sole consideration is cash, either (i) Holder shall exercise its
conversion or purchase right under this Warrant and such exercise
will be deemed effective immediately prior to the consummation of
such Acquisition or (ii) if Holder elects not to exercise the
Warrant, this Warrant will expire upon the consummation of such
Acquisition (subject to the automatic conversion provisions of
Section 5.8 below). The Company shall provide Holder
with written notice of its request relating to the foregoing
(together with such reasonable information as Holder may request in
connection with such contemplated Acquisition giving rise to such
notice), which is to be delivered to Holder not less than ten (10)
days prior to the closing of the proposed Acquisition.
(B) Upon
the written request of the Company, Holder agrees that, in the
event of an Acquisition that is an “arms length” sale
of all or substantially all of the Company’s assets (and only
its assets) to a third party that is not an Affiliate (as defined
below) of the Company (a “True Asset Sale”), either (i)
Holder shall exercise its conversion or purchase right under this
Warrant and such exercise will be deemed effective immediately
prior to the consummation of such Acquisition or (ii) if Holder
elects not to exercise the Warrant, this Warrant will continue
until the Expiration Date if the Company continues as a going
concern following the closing of any such True Asset
Sale. The Company shall provide Holder with written
notice of its request relating to the foregoing (together with such
reasonable information as Holder may request in connection with
such contemplated Acquisition giving rise to such notice), which is
to be delivered to Holder not less than ten (10) days prior to the
closing of the proposed Acquisition.
(C) Upon
the closing of any Acquisition other than those particularly
described in subsections (A) and (B) above, the successor entity
shall assume the obligations of this Warrant, and this Warrant
shall be exercisable for the same securities, cash, and property as
would be payable for the Shares issuable upon exercise of the
unexercised portion of this Warrant as if such Shares were
outstanding on the record date for the Acquisition and subsequent
closing. The Warrant Price and/or number of Shares shall
be adjusted accordingly.
As used herein
“ Affiliate ” shall mean any person or entity
that owns or controls directly or indirectly ten percent (10%) or
more of the stock of Company, any person or entity that controls or
is controlled by or is under common control with such persons or
entities, and each of such person’s or entity’s
officers, directors, joint venturers or partners, as
applicable.
1.7
Additional Shares . Upon the funding of Tranche
Two (as defined in the Loan Agreement), the Company shall be deemed
to have automatically granted to Holder, in addition to the number
of Shares which this Warrant can otherwise be exercised for by
Holder, the right to purchase that number of additional Shares,
rounded upward to the nearest whole number, equal to 150,000
divided by the Warrant Price (such additional shares being called
the “Additional Shares”).
ARTICLE 2.
ADJUSTMENTS TO THE SHARES .
2.1
Stock Dividends, Splits, Etc . If, at any time
following the Issue Date, the Company declares or pays a dividend
on the Shares payable in common stock, or other securities, then
upon exercise of this Warrant, for each Share acquired, Holder
shall receive, without cost to Holder, the total number and kind of
securities to which Holder would have been entitled had Holder
owned the Shares of record as of the date the dividend
occurred. If the Company subdivides the Shares by
reclassification or otherwise into a greater number of shares, the
number of shares purchasable hereunder shall be proportionately
increased and the Warrant Price shall be proportionately
decreased. If the outstanding shares are combined or
consolidated, by reclassification or otherwise, into a lesser
number of shares, the Warrant Price shall be proportionately
increased and the number of Shares shall be proportionately
decreased.
2.2
Reclassification, Exchange, Combinations or Substitution
. Upon any reclassification, exchange, substitution, or
other event that results in a change of the number and/or class of
the securities issuable upon exercise or conversion of this
Warrant, Holder shall be entitled to receive, upon exercise or
conversion of this Warrant, the number and kind of securities and
property that Holder would have received for the Shares if this
Warrant had been exercised immediately before such
reclassification, exchange, substitution, or other
event. The Company or its successor shall promptly issue
to Holder an amendment to this Warrant setting forth the number and
kind of such new securities or other property issuable upon
exercise or conversion of this Warrant as a result of such
reclassification, exchange, substitution or other event that
results in a change of the number and/or class of securities
is
|